Clinical Trial Update: Clinical Study of Neoadjuvant Targeted Therapy for Ameloblastoma [Phase 2]

View source ↗

Summary

A Phase 2 neoadjuvant targeted therapy trial for ameloblastoma with BRAF V600E mutation is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ameloblastoma

Snippet

Sponsor: Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University | Conditions: Ameloblastoma, BRAF V600E Mutation Positive | Phase 2 | Status: RECRUITING